Salvia BioElectronics
Category: AI in Healthcare
Developing minimally invasive bioelectronic foils for neuromodulation therapy to treat chronic migraine and other neurological disorders. Salvia BioElectronics was founded in 2017. The company is led by Hubert Martens. Based in Eindhoven, Noord-Brabant, The Netherlands. Team size: 50. Total funding raised: $88.4M. Latest round: Series B. Key investors include Innovation Industries, Invest-NL, EIC Fund, Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, BOM, Thuja Capital.
- Founded
- 2017
- Headquarters
- Eindhoven, Noord-Brabant, The Netherlands
- Team size
- 50
- Total funding
- $88.4M
Value proposition
Offers a novel, minimally invasive, and personalized neuromodulation therapy with potentially fewer side effects compared to traditional treatments and existing neurostimulation devices.
Products and solutions
Implantable neurostimulation system using ultra-thin bioelectronic foil technology (MySalvia Therapy)
Unique value
Ultra-thin, conforming bioelectronic foils that adapt to the anatomy of the head, allowing for a minimally invasive procedure. Personalized therapy tailored to individual patient needs.
Target customer
Patients suffering from chronic migraine for whom other therapies have failed.
Industries served
Healthcare, Medical Devices, Neurology
Technology advantage
Minimally invasive implantation, potentially greater efficacy and fewer side effects for chronic migraine. Breakthrough Device Designation from FDA may expedite market access.
How they differentiate
Focus on ultra-thin, conforming bioelectronic foils specifically designed for the head's anatomy for migraine treatment, offering a minimally invasive approach.
Main competitors
Medtronic, Boston Scientific, Nevro, ShiraTronics, Theranica
Key partnerships
MedTech Innovator Accelerator 2024, Erasmus MC (Rotterdam clinical trial collaboration), St. Antonius Hospital Utrecht/Nieuwegein (Clinical trial collaboration), OPZuid (CLUSTERSENSE project funding, Oct 2025-Sep 2028), Mayo Clinic Arizona, UCL Queen Square Institute of Neurology, Thomas Jefferson University, University of Rochester, University of Maryland, University Hospital Essen (RECLAIM-II study collaborators)
Notable customers
Clinical trial patients, Erasmus MC (first patient treated in the Netherlands), AZ Delta Roeselare, ZAS Antwerp, Jessa Hospital Hasselt, AZ Sint-Jan Bruges, AZ Groeninge Kortrijk, AZ Oostende (Belgian RECLAIM study sites)
Major milestones
Secured multiple funding rounds, including a significant Series A., Received FDA Breakthrough Device Designation for its neurostimulation system., Initiated and ongoing RECLAIM clinical study in multiple countries (Belgium, Australia, Netherlands)., First patient implanted in the Netherlands as part of the clinical study., Initiated RECLAIM-II, the first FDA IDE-approved pivotal trial of implantable neuromodulation for resistant migraine in the U.S. (presented at AHS 2026)., Initiated RESPONSE-II cluster headache feasibility study in the Netherlands (2026)., Launched CLUSTERSENSE project (OPZuid-funded, Oct 2025-Sep 2028) developing AI-driven pain recognition for personalized neurostimulation.
Growth metrics
Team grown to 50+ employees representing 17 nationalities. Selected for MedTech Innovator Accelerator 2024. Ongoing RECLAIM clinical study. RECLAIM-II FDA IDE-approved pivotal trial initiated in the U.S. (2026). RESPONSE-II cluster headache study launched in the Netherlands (2026). CLUSTERSENSE AI-driven pain recognition project underway (2025-2028).
Market positioning
Pioneering minimally invasive bioelectronic solutions for chronic migraine, targeting patients with refractory conditions.
Geographic focus
Initial focus on Europe (Netherlands, Belgium) and Australia, with plans for U.S. market entry facilitated by FDA Breakthrough Device Designation.
Patents and IP
Patents pending
About Hubert Martens
Hubert Martens is a seasoned medical device entrepreneur with a strong background in neurostimulation. He co-founded Salvia BioElectronics in 2017 and has since been leading the company's efforts in developing innovative therapies for chronic migraine. His experience spans various leadership roles in the medical technology industry, including positions at Sapiens Steering Brain Stimulation and Medtronic. He holds a PhD from Leiden University.
More AI in Healthcare companies
Official website: https://www.salviabioelectronics.com/